Literature DB >> 18778569

Review of measures of neuropathic pain.

Mark P Jensen1.   

Abstract

Eight measures of neuropathic pain exist that have been designed to discriminate neuropathic from non-neuropathic pain and detect treatment effects. The current paper describes these measures and summarizes the evidence supporting their validity. Based on the available evidence, the Leeds Assessment of Neuropathic Signs and Symptoms appears to have the most empirical support as a measure that distinguishes patients with and without neuropathic pain in patient samples presenting with mixed chronic pain problems. However, given the lack of overlap in measures designed for this purpose, it is likely that the validity of any one measure could be improved by incorporating items from the others. The Neuropathic Pain Scale (NPS) has the most empirical support as a measure of treatment outcome, although a new measure that includes the NPS items (the Pain Quality Assessment Scale) will likely prove to be even more useful, because it includes pain descriptors common to people with neuropathic and other chronic pain conditions not included on the NPS.

Entities:  

Mesh:

Year:  2006        PMID: 18778569     DOI: 10.1007/s11916-006-0041-z

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  32 in total

1.  Course of symptoms and quality of life measurement in Complex Regional Pain Syndrome: a pilot survey.

Authors:  B S Galer; J Henderson; J Perander; M P Jensen
Journal:  J Pain Symptom Manage       Date:  2000-10       Impact factor: 3.612

2.  Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale.

Authors:  B S Galer; M P Jensen
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial.

Authors:  Mark P Jensen; Michael Friedman; Daniel Bonzo; Patricia Richards
Journal:  Clin J Pain       Date:  2006-01       Impact factor: 3.442

4.  Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design.

Authors:  M G Byas-Smith; M B Max; J Muir; A Kingman
Journal:  Pain       Date:  1995-03       Impact factor: 6.961

5.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Authors:  David J Rog; Turo J Nurmikko; Tim Friede; Carolyn A Young
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

6.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

Authors:  Didier Bouhassira; Nadine Attal; Haiel Alchaar; François Boureau; Bruno Brochet; Jean Bruxelle; Gérard Cunin; Jacques Fermanian; Patrick Ginies; Aurélie Grun-Overdyking; Hélène Jafari-Schluep; Michel Lantéri-Minet; Bernard Laurent; Gérard Mick; Alain Serrie; Dominique Valade; Eric Vicaut
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

7.  Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain.

Authors:  Bradley S Galer; Arnold R Gammaitoni; Napoleon Oleka; Mark P Jensen; Charles E Argoff
Journal:  Curr Med Res Opin       Date:  2004       Impact factor: 2.580

8.  Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale.

Authors:  Arnold R Gammaitoni; Bradley S Galer; Roland Onawola; Mark P Jensen; Charles E Argoff
Journal:  Curr Med Res Opin       Date:  2004       Impact factor: 2.580

9.  Development of a neuropathic pain questionnaire.

Authors:  Steven J Krause; Misha-Miroslav Backonja
Journal:  Clin J Pain       Date:  2003 Sep-Oct       Impact factor: 3.442

10.  Development and validation of the Neuropathic Pain Symptom Inventory.

Authors:  Didier Bouhassira; Nadine Attal; Jacques Fermanian; Haiel Alchaar; Michèle Gautron; Etienne Masquelier; Sylvie Rostaing; Michel Lanteri-Minet; Elisabeth Collin; Jacques Grisart; François Boureau
Journal:  Pain       Date:  2004-04       Impact factor: 6.961

View more
  7 in total

1.  Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool.

Authors:  Cielito Reyes-Gibby; Phuong Khanh Morrow; Michael I Bennett; Mark P Jensen; Sanjay Shete
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

Review 2.  Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature.

Authors:  Amanda M Brandow; Rebecca A Farley; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2015-05-13       Impact factor: 3.167

3.  Central Neuropathic Pain in Spinal Cord Injury.

Authors:  Sujin Lee; Xing Zhao; Maya Hatch; Sophia Chun; Eric Chang
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

4.  Neuropathic pain in patients with sickle cell disease.

Authors:  Amanda M Brandow; Rebecca A Farley; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2013-10-26       Impact factor: 3.167

5.  An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease.

Authors:  Barth Wilsey; Thomas D Marcotte; Reena Deutsch; Holly Zhao; Hannah Prasad; Amy Phan
Journal:  J Pain       Date:  2016-06-07       Impact factor: 5.820

6.  A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.

Authors:  Barth L Wilsey; Reena Deutsch; Emil Samara; Thomas D Marcotte; Allan J Barnes; Marilyn A Huestis; Danny Le
Journal:  J Pain Res       Date:  2016-08-31       Impact factor: 3.133

7.  Efficacy of Perioperative Intercostal Analgesia via a Multimodal Analgesic Regimen for Chronic Post-Thoracotomy Pain During Postoperative Follow-Up: A Big-Data, Intelligence Platform-Based Analysis.

Authors:  Yijin Yu; Lingyan Cui; Lu Qian; Min Lei; Qi Bao; Qingxin Zeng; Zhao Chen; Shaohua Xu; Junran Xie
Journal:  J Pain Res       Date:  2021-07-05       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.